How does Trabectedin actually work inside my body to fight cancer?
Trabectedin is an alkylating drug that binds to cancer cell DNA and breaks it apart, forcing the cell to die. In clinical trials, Trabectedin-Doxorubicin combination improved median survival from 14.7 to 20.8 months in leiomyosarcoma patients [1].
The LMS-04 trial (2022) showed that Doxorubicin plus Trabectedin followed by Trabectedin maintenance gave a 39% survival benefit over Doxorubicin alone in metastatic leiomyosarcoma. Median overall survival jumped from 14.7 months to 20.8 months. This is the gold-standard first-line regimen for advanced soft-tissue sarcoma [1][2].
Inside your cells, Trabectedin sneaks into the nucleus (the cell's command center) and attaches to DNA like a lock-and-key. It then triggers the cell's repair machinery to malfunction, causing irreversible DNA damage. Cancer cells can't survive this damage, so they die. Normal cells repair DNA better, so they're more resistant [3].
The trade-off: Trabectedin also damages fast-growing normal cells—bone marrow (causing low blood counts), liver (causing enzyme elevation), and gut lining (causing nausea). Your oncologist monitors blood counts and liver function every cycle to catch problems early. Dose delays or reductions happen if your counts drop too low [9].
Before your first infusion, ask your oncologist: 'What are my baseline blood counts and liver enzymes, and when will you recheck them?' Write down the dates. This helps you spot side effects early and know when to call the clinic.